World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
92
Citations
36577
World Ranking
11181
National Ranking
5751

Maurie Markman publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Maurie Markman sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 914 publications — 92nd percentile

92% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Maurie Markman D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Maurie Markman sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 92 D-Index — 45th percentile

45% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Maurie Markman is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on medical and molecular biology fields, with substantial contributions to cancer research and reproductive medicine.

The scientist's main fields of study include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Markman's work covers several subfields, notably:

  • Cancer Research
  • Reproductive Medicine
  • Oncology
  • Pulmonary and Respiratory Medicine
  • Epidemiology

The main research topics they address are:

  • Cancer Genomics and Diagnostics
  • Ovarian cancer diagnosis and treatment
  • Renal cell carcinoma treatment
  • Pancreatic and Hepatic Oncology Research
  • Intraperitoneal and Appendiceal Malignancies
  • Endometrial and Cervical Cancer Treatments
  • Molecular Biology Techniques and Applications

Maurie Markman has contributed to numerous scientific publications across various venues. Frequent publication outlets include:

  • Journal of Clinical Oncology
  • Gynecologic Oncology Reports
  • Gynecologic Oncology
  • Future Virology
  • Cancer Research

Recent papers by Markman highlight topics in ovarian and pancreatic cancers and include:

  • What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer, 2022, Gynecologic Oncology
  • Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgery, 2020, Gynecologic Oncology Reports
  • Mutational landscape of pancreatic adenocarcinoma identified by prospective clinical sequencing in a nationwide cancer network, 2022, Journal of Clinical Oncology
  • Racial differences in the mutational landscape of serous endometrial cancer, 2022, Journal of Clinical Oncology
  • 36 Mutational landscape of low-grade serous carcinoma of the ovary, 2022, Gynecologic Oncology Reports

Their collaborative network includes frequent co-authors such as:

  • Vicki Doctor
  • Amber Moran
  • Julian C. Schink
  • Julia A. Elvin
  • Natalie Godbee

Best Publications

  • Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group

    Maurie Markman;Brian N. Bundy;David S. Alberts;Jeffrey M. Fowler

  • Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.

    M Markman;R Rothman;T Hakes;B Reichman

  • Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

    William E. Winter;G. Larry Maxwell;Chunqiao Tian;Jay W. Carlson

  • Lysophosphatidic Acid as a Potential Biomarker for Ovarian and Other Gynecologic Cancers

    Yan Xu;Zhongzhou Shen;Donald W. Wiper;Minzhi Wu

  • Ovarian Cancer: Screening, Treatment, and Follow-up

    Vicki Seltzer;Bruce H. Drukker;Brenda W. Gillespie;Lynn M. Gossfeld

  • Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients With Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial

    Maurie Markman;P.Y. Liu;Sharon Wilczynski;Bradley Monk

  • Clinical Features of Hypersensitivity Reactions to Carboplatin

    Maurie Markman;Alexander Kennedy;Kenneth Webster;Paul Elson

  • Paclitaxel in cancer therapy.

    Tarek M Mekhail;Maurie Markman

  • Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer

    Bryan T.J. Hennessy;Kirsten M. Timms;Mark S. Carey;Alexander Gutin

  • Second-line treatment of ovarian cancer.

    Maurie Markman;Michael A. Bookman

  • Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study.

    M Markman;E Rowinsky;T Hakes;B Reichman

  • Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.

    Howard D. Homesley;Virginia Filiaci;Maurie Markman;Pincas Bitterman

  • Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study

    Maurie Markman;John Blessing;Stephen C. Rubin;Joseph Connor

  • Phase II Trial of Weekly Single-Agent Paclitaxel in Platinum/Paclitaxel-Refractory Ovarian Cancer

    Maurie Markman;James Hall;Daniel Spitz;Sheldon Weiner

  • Long-Term Survival of Advanced Refractory Ovarian Carcinoma Patients with Small-Volume Disease Treated with Intraperitoneal Chemotherapy

    Stephen B. Howell;Soloman Zimm;Maurie Markman;Ian S. Abramson

  • Intraperitoneal antineoplastic drug delivery: rationale and results

    Maurie Markman

  • RESPONSES TO SALVAGE CHEMOTHERAPY IN OVARIAN CANCER: A CRITICAL NEED FOR PRECISE DEFINITIONS OF THE TREATED POPULATION

    M Markman;W Hoskins

  • Duration of Response to Second-Line, Platinum-Based Chemotherapy for Ovarian Cancer: Implications for Patient Management and Clinical Trial Design

    Maurie Markman;Jonathan Markman;Kenneth Webster;Kristine M. Zanotti

  • Clinical Cancer Advances 2008: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology

    Eric Winer;Julie Gralow;Lisa Diller;Beth Karlan

  • Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin.

    M Markman;B Reichman;T Hakes;W Jones

Frequent Co-Authors

William J. Hoskins
William J. Hoskins Memorial Sloan Kettering Cancer Center
Stephen C. Rubin
Stephen C. Rubin University of Pennsylvania
Stephen B. Howell
Stephen B. Howell University of California, San Diego
Richard R. Barakat
Richard R. Barakat Northwell Health
David S. Alberts
David S. Alberts University of Arizona
Mark G. Kris
Mark G. Kris Memorial Sloan Kettering Cancer Center
Lynn M. Schuchter
Lynn M. Schuchter University of Pennsylvania
Yoshihiko Maehara
Yoshihiko Maehara Kyushu University
Raymond Sawaya
Raymond Sawaya The University of Texas MD Anderson Cancer Center
Patricia A. Ganz
Patricia A. Ganz University of California, Los Angeles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a medical career in the USA involves various educational routes, including flexible online options for those seeking advanced nursing or entry-level roles. Accelerated online programs are gaining popularity, allowing students to earn credentials faster and join the healthcare workforce sooner.

For nurses aiming to reach the highest clinical degrees, several universities offer the shortest post master's DNP program, letting experienced nurses complete their Doctor of Nursing Practice in less time. Additionally, various DNP online programs are designed for flexibility and accessibility, ideal for working professionals balancing studies and career.

If you’re interested in psychiatric nursing, some schools provide the shortest post master's PMHNP online programs, preparing nurses for specialized roles in mental health in record time.

Those starting out can consider entry-level options, such as a LPN program online, which enables rapid entry into the nursing field.

With these diverse choices, prospective healthcare professionals can find pathways that match their personal goals, timelines, and learning preferences.

Best Scientists Citing Maurie Markman

Trending Scientists

Recently Published Articles